Prima BioMed Net Profit Margin 2010-2021 | IMMP
Prima BioMed net profit margin from 2010 to 2021. Net profit margin can be defined as net Income as a portion of total sales revenue.
|Prima BioMed Net Profit Margin Historical Data
||TTM Net Income
||Medical - Biomedical and Genetics
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.